COMy 2023 | The value of selinexor as a second-line treatment option for patients with R/R myeloma
Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, comments on the use of selinexor, a selective exportin-1 (XPO1) inhibitor, as a second-line treatment in patients with relapsed/refractory multiple myeloma (R/R MM). Dr Cerchione notes that selinexor is currently approved in combination with bortezomib and dexamethasone based on the results of the BOSTON clinical trial (NCT03110562), but further trials should evaluate its efficacy in combination with other agents. Dr Cerchione further notes advantages of selinexor and discusses approaches to manage associated toxicities. This interview took place at the 9th World Congress on Controversies in Multiple Myeloma (COMy) 2023, held in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
